文献速递糖尿病

降糖药物对胰高血糖素和C肽反应的差异化纵向影响:GRADE研究

Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
PubMed 文献 · Diabetes Care · 2026-01-01

本研究基于GRADE随机对照试验,在5047例二甲双胍治疗的2型糖尿病患者中比较四种降糖药,并在724例亚组中评估α细胞功能。结果显示基线及治疗中α细胞功能与血糖恶化无关,而β细胞功能指标CPI的变化与主要代谢结局相关,CPI每增加1个标准差风险降低17%。四种药物对胰高血糖素反应无明确差异。

要点

  • α细胞功能(空腹胰高血糖素及GGI)与HbA1c≥7.0%的主要代谢结局无关。
  • β细胞功能指标CPI的变化与主要代谢结局显著相关,CPI每升高1-SD风险降低17%。
  • 四种降糖药对胰高血糖素反应无明确差异,选药应主要关注对β细胞功能的影响。

核心结论

  • 四种降糖药对α细胞功能影响模式不同,但α细胞功能与血糖恶化无关。
  • 治疗2型糖尿病选药应主要关注药物对β细胞功能的影响。

研究设计与样本

  • 多中心随机研究,5047例≥30岁、二甲双胍1000-2000mg/日、HbA1c 6.8%-8.5%的2型糖尿病患者。
  • 随机接受甘精胰岛素U100、格列美脲、利拉鲁肽或西格列汀治疗。
  • 在724例亚组中评估基线及纵向α细胞功能(空腹胰高血糖素、胰高血糖素指数GGI)和β细胞功能(空腹C肽、C肽指数CPI)。

主要发现

  • 基线空腹胰高血糖素和GGI与主要代谢结局无关(2 df;P=0.55),β细胞指标与之相关(2 df;P=0.04)。
  • 治疗相关空腹胰高血糖素、GGI和空腹C肽变化与主要代谢结局无关,CPI变化相关(未调整P<0.05,调整α细胞功能后P<0.001)。
  • CPI每增加1个标准差,主要代谢结局风险降低17%。
  • 四种药物对胰高血糖素反应无明确差异。

临床怎么用

  • 在二甲双胍基础上选择降糖药时,应优先考虑对β细胞功能影响更有利的药物。
  • α细胞功能指标不宜作为评估降糖疗效或预测血糖恶化的主要依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the longitudinal effects on α-cell function of four classes of glucose-lowering agents added to metformin in adults with type 2 diabetes. RESEARCH DESIGN AND METHODS: In a multicenter, randomized study, 5,047 participants ≥30 years of age with type 2 diabetes taking 1,000-2,000 mg metformin daily, HbA1c 6.8%-8.5%, were randomized to receive insulin glargine U100, glimepiride, liraglutide, or sitagliptin. In a subset of 724 participants, baseline and longitudinal measures of α-cell function were assessed as the fasting glucagon concentration and change in glucagon from fasting to 30 min following oral glucose (glucagon index [GGI]). Whether these measures and those of β-cell function (fasting C-peptide and C-peptide index [CPI]) were related to the primary metabolic outcome (HbA1c ≥7.0%) was examined. RESULTS: Baseline fasting glucagon and GGI were not associated with the primary metabolic outcome (2 df; P = 0.55), whereas the β-cell measures were (2 df; P = 0.04). Treatment-associated changes in fasting glucagon, GGI, and fasting C-peptide were not associated with the primary metabolic outcome, while changes in CPI were, in models unadjusted (P < 0.05) or adjusted (P < 0.001) for α-cell function. A 1-SD increase in CPI was associated with a 17% reduction in the risk of the primary metabolic outcome. There were no clear differential effects of the medications on glucagon responses. CONCLUSIONS: There were different patterns of effects of the four glucose-lowering medications on the α-cell, with no relationship of α-cell function with worsening glycemia. Thus, in treating type 2 diabetes, for choice of medication(s) the focus should primarily be on their impact on β-cell function.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Kahn SE, Tripputi M, Lachin JM, et al. Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2026. PMID: 41432725. doi:10.2337/dc25-2186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。